e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Preclinical models for the development of new drugs for respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary alveolar proteinosis: iPS derived macrophages as in-vitro disease model and potential source for novel gene and cell therapies
C. Happle, N. Lachmann, M. Wetzke, D. Lüttge, M. Ackermann, A. Mucci, J. Skuljec, S. Merkert, A. Schambach, T. Moritz, G. Hansen (Hannover, Germany)
Source:
Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Session:
Preclinical models for the development of new drugs for respiratory diseases
Session type:
Thematic Poster Session
Number:
689
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Happle, N. Lachmann, M. Wetzke, D. Lüttge, M. Ackermann, A. Mucci, J. Skuljec, S. Merkert, A. Schambach, T. Moritz, G. Hansen (Hannover, Germany). Pulmonary alveolar proteinosis: iPS derived macrophages as in-vitro disease model and potential source for novel gene and cell therapies. Eur Respir J 2013; 42: Suppl. 57, 689
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Related content which might interest you:
Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Alveolar type II cells transplantation in pulmonary fibrosis: Effect on the lung macrophage activation
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
The effects of tobramycin on pulmonary fibroblast function
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
The effect of
in vitro
culture methods on corticosteroid sensitivity in COPD alveolar macrophages
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013
Characterization of M1 and M2 macrophages in human lung tissue
Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Year: 2013
Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP)
Source: International Congress 2014 – ILDs 2
Year: 2014
Pulmonary alveolar proteinosis due to heterozygous mutation in OAS1: Treatment of a novel disease with whole lung lavages and stem cell transplantation
Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans
Year: 2019
Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Role of HGF in the healthy and injured lung
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Late Breaking Abstract - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes
Source: International Congress 2018 – ILDs: From bench to bedside
Year: 2018
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Induced pluripotent stem cells conditioned media (iPS-cm) modulates macrophage phenotype in the fibrotic lung
Source: International Congress 2014 – Lung cell biology in injury and repair
Year: 2014
The use of immunohistochemical stains to identify Langerhans cells in pulmonary histiocytosis
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
The secretome of induced pluripotent stem cells (iPSC) modulates macrophage phenotype in the fibrotic lung
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept